Logo image of ACLX

ARCELLX INC (ACLX) Stock Fundamental Analysis

USA - NASDAQ:ACLX - US03940C1009 - Common Stock

85.07 USD
+2.83 (+3.44%)
Last: 10/3/2025, 8:20:47 PM
85.07 USD
0 (0%)
After Hours: 10/3/2025, 8:20:47 PM
Fundamental Rating

3

ACLX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. ACLX has a great financial health rating, but its profitability evaluates not so good. ACLX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACLX had negative earnings in the past year.
In the past year ACLX has reported a negative cash flow from operations.
In the past 5 years ACLX always reported negative net income.
In the past 5 years ACLX reported 4 times negative operating cash flow.
ACLX Yearly Net Income VS EBIT VS OCF VS FCFACLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.37%, ACLX is in the better half of the industry, outperforming 66.79% of the companies in the same industry.
The Return On Equity of ACLX (-47.93%) is better than 66.79% of its industry peers.
Industry RankSector Rank
ROA -30.37%
ROE -47.93%
ROIC N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ACLX Yearly ROA, ROE, ROICACLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ACLX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACLX Yearly Profit, Operating, Gross MarginsACLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

7

2. Health

2.1 Basic Checks

ACLX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACLX has been increased compared to 1 year ago.
Compared to 5 years ago, ACLX has more shares outstanding
Compared to 1 year ago, ACLX has an improved debt to assets ratio.
ACLX Yearly Shares OutstandingACLX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ACLX Yearly Total Debt VS Total AssetsACLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 10.29 indicates that ACLX is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.29, ACLX belongs to the top of the industry, outperforming 84.33% of the companies in the same industry.
There is no outstanding debt for ACLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.29
ROIC/WACCN/A
WACC10%
ACLX Yearly LT Debt VS Equity VS FCFACLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

ACLX has a Current Ratio of 3.81. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
ACLX has a Current ratio of 3.81. This is comparable to the rest of the industry: ACLX outperforms 44.22% of its industry peers.
ACLX has a Quick Ratio of 3.81. This indicates that ACLX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.81, ACLX perfoms like the industry average, outperforming 46.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.81
Quick Ratio 3.81
ACLX Yearly Current Assets VS Current LiabilitesACLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

ACLX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -228.85%.
The Revenue for ACLX has decreased by -60.64% in the past year. This is quite bad
EPS 1Y (TTM)-228.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.31%
Revenue 1Y (TTM)-60.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-72.41%

3.2 Future

Based on estimates for the next years, ACLX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.93% on average per year.
ACLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.17% yearly.
EPS Next Y-105.44%
EPS Next 2Y-33.54%
EPS Next 3Y-10.57%
EPS Next 5Y24.93%
Revenue Next Year-64.48%
Revenue Next 2Y5.05%
Revenue Next 3Y27.66%
Revenue Next 5Y42.17%

3.3 Evolution

ACLX Yearly Revenue VS EstimatesACLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ACLX Yearly EPS VS EstimatesACLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACLX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACLX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACLX Price Earnings VS Forward Price EarningsACLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACLX Per share dataACLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as ACLX's earnings are expected to decrease with -10.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.54%
EPS Next 3Y-10.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACLX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCELLX INC

NASDAQ:ACLX (10/3/2025, 8:20:47 PM)

After market: 85.07 0 (0%)

85.07

+2.83 (+3.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-18 2025-11-18/amc
Inst Owners101.69%
Inst Owner Change-2.9%
Ins Owners1.33%
Ins Owner Change-2.41%
Market Cap4.72B
Analysts85.83
Price Target115.33 (35.57%)
Short Float %14.78%
Short Ratio13.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-18.41%
Min EPS beat(2)-46.25%
Max EPS beat(2)9.43%
EPS beat(4)1
Avg EPS beat(4)-24.54%
Min EPS beat(4)-51.89%
Max EPS beat(4)9.43%
EPS beat(8)4
Avg EPS beat(8)12.62%
EPS beat(12)4
Avg EPS beat(12)-25.07%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-52.93%
Min Revenue beat(2)-60.26%
Max Revenue beat(2)-45.6%
Revenue beat(4)0
Avg Revenue beat(4)-43.51%
Min Revenue beat(4)-60.26%
Max Revenue beat(4)-25.74%
Revenue beat(8)3
Avg Revenue beat(8)27.83%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.38%
EPS NY rev (1m)0.49%
EPS NY rev (3m)1.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.53%
Revenue NY rev (1m)-11.76%
Revenue NY rev (3m)-37.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.8
P/FCF N/A
P/OCF N/A
P/B 12.03
P/tB 12.03
EV/EBITDA N/A
EPS(TTM)-3.42
EYN/A
EPS(NY)-3.57
Fwd EYN/A
FCF(TTM)-2.22
FCFYN/A
OCF(TTM)-2.13
OCFYN/A
SpS1.03
BVpS7.07
TBVpS7.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.37%
ROE -47.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.93%
ROA(5y)-37.97%
ROE(3y)-43.4%
ROE(5y)-50.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 80.04%
Cap/Sales 8.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.81
Quick Ratio 3.81
Altman-Z 10.29
F-Score2
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)494.02%
Cap/Depr(5y)435.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-228.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-84.31%
EPS Next Y-105.44%
EPS Next 2Y-33.54%
EPS Next 3Y-10.57%
EPS Next 5Y24.93%
Revenue 1Y (TTM)-60.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-72.41%
Revenue Next Year-64.48%
Revenue Next 2Y5.05%
Revenue Next 3Y27.66%
Revenue Next 5Y42.17%
EBIT growth 1Y-165.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-105.01%
EBIT Next 3Y1.84%
EBIT Next 5Y22.46%
FCF growth 1Y-217.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-202.59%
OCF growth 3YN/A
OCF growth 5YN/A